



ARTIVION™

Aorta + Innovation + Vision

Corporate Overview

February 2026

FORWARD-LOOKING STATEMENT

Statements made in this presentation that look forward in time or that express management's beliefs, expectations, or forecasts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our belief that we can continue to drive sustained double digit revenue growth and EBIDTA growth at twice the rate of revenue growth, as a result of our base business, our high growth On-X and stent graft businesses and our leverageable global infrastructure; our estimates of the size of the total addressable markets and growth profiles for our preservation services (human tissue), mechanical heart valves, stents and surgical sealants; our estimates of the size of the total addressable markets and growth rates for E-vita OPEN NEO, AMDS, NEXUS, E-nside, Artivex and E-tegra; our estimates relating the conduct of and timelines for enrollment of our ongoing and planned clinical trials and regulatory approvals, including PERSEVERE, ARTIZEN, Endospan's TRIOMPHE, and for ARCEVO and TAAA Systems; our beliefs that our products will result in improved patient outcomes; our expectations regarding future constant currency revenue growth in 2026 compared to 2025; our estimates and related expectations regarding increased incremental cash flow by revenue growth and gross margin and adjusted EBITDA margin expansion; our expectation that we will be free cash flow positive and the timing thereof; our expectation that we will continue to decrease net debt leverage by year end 2026; and our belief and expectations about our future revenue, year over year growth and growth drivers, earnings, adjusted EBITDA and other financial measures and related information.


These forward-looking statements are subject to a number of risks, uncertainties, estimates and assumptions that may cause actual results to differ materially from current expectations, including but not limited to the risks and uncertainties relating to our international operations; regulatory developments; clinical trials and regulatory approvals; anticipated benefits of our credit facility and other agreements; and market opportunities and commercialization. These risks and uncertainties include the risk factors detailed in documents that we file with or furnish to the Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2025. Artivion does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.

AN AORTIC DISEASE-FOCUSED COMPANY

~\$444 MILLION FY25 REVENUE; ~\$90 MILLION FY25 EBITDA

ARTIVION™

AORTIC VALVE STENOSIS <65 YRS



ALLOGRAFT VALVES



MECHANICAL VALVES

AORTIC DISSECTION & ANEURYSMS



Dissection



Aneurysm



STENT GRAFTS



SURGICAL SEALANT

EXPERIENCED LEADERS

ARTIVION™

Decades of combined experience and leadership in the medical device industry.



Pat Mackin

Chairman, President & CEO

Previously with
Medtronic



Lance Berry
EVP, COO & CFO



John Davis
Chief Commercial Officer



Jean Holloway
SVP, GC, CCO & CS



Marshall Stanton
SVP, Clinical Research
& Chief Medical Officer



Drew Green
SVP, Regulatory
Affairs and Quality



Jason Asper
SVP & Chief Strategy
and Digital Officer



Robert Thomson
VP, Research &
Development



DRIVING SUSTAINED DOUBLE-DIGIT REVENUE GROWTH & 2x+ EBITDA GROWTH

Highly Differentiated,
Highly Defendable
Base Business



High Growth,
High Margin
Businesses




Gross Margin
Expansion +
SG&A Leverage



Double Digit
Revenue
Growth

2x+
EBITDA Growth



Data for Full Year Ended December 31, 2025

- ✓ Gross margin expansion through mix
- ✓ ~200 direct sales employees globally
- ✓ Global G&A Infrastructure

HIGHLY DIFFERENTIATED, HIGHLY DEFENDABLE BASE BUSINESS

ARTIVION™

Strong Positions in Segments with Limited Competition and No Anticipated New Entrants

| | | Differentiation | 2025 Revenue | Global TAM | Market Position/ Share | # Major Competitors | Growth Profile |
|------------------------------------------------------------------------------------|-------------------------------------------------|--------------------------------------------------------------|--------------|---------------|------------------------|---------------------|-------------------------|
|  | Preservation Services (CryoValve® SG) | Only Decellularized Pulmonary Valve | \$96M | \$150M | #1 / 65% | 2* | Mid Single Digit |
|  | Surgical Sealant (BioGlue) | Only Cardiac Sealant with Acute Type A Dissection Indication | \$77M | \$260M | #2 / 28% | 3 | Mid Single Digit |

ON-X AORTIC HEART VALVE POST APPROVAL STUDY (PAS) VS. PROACT IDE

ARTIVION™


5-year real-world results demonstrate even better patient outcomes than predicted by the On-X aortic heart valve PROACT IDE study

Only Mechanical Heart Valve Maintained at a Low INR of 1.5 to 2.0



| | Post Approval Study (5 Years) ¹ | PROACT IDE Study ² |
|-------------------------------------------|--------------------------------------------|-------------------------------|
| Reduction in Major Events** | 66% | 23% |
| Reduction in Major Bleeding | 87% | 60% |
| INR Monitoring Method (% Clinic / % Home) | 84% / 16% | 0% / 100% |

COMPOSITE PRIMARY ENDPOINT
5.39% vs 1.83%, p<0.0001; N=229



**Composite of Thromboembolism, Valve Thrombosis, and Major Bleeding

1. Gerdisch, et al. for the On-X Aortic Post-Approval Study Investigators. (2024, April 27-30) Low-Dose Warfarin with a Novel Mechanical Aortic Valve: Interim Registry Results at 5-Year Follow-up. [Presentation]. AATS. Toronto, Canada. 2. Puskas J, et al. (2014). Reduced anticoagulation after mechanical aortic valve replacement: Interim results from the Prospective Randomized On-X® Valve Anticoagulation Clinical Trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg, 147(4), 1201-11. *Artivion data on file, weighted average of control groups from FDA Premarket Approval P000037 S030 and IDE trial G050208.

On-X: High Growth, High Margin, with Market Upside

ARTIVION™

New Recently Published Data Across Three Leading Journals to Drive Potential \$100 million Upside to Addressable U.S. Mechanical Heart Valve Market

5-year PAS Data Presented in April 2024¹

- ✓ Demonstrated 87% Reduction in Major Bleeding
- ✓ Validated On-X as Only Mechanical Heart Valve Safely Maintained at a Low INR of 1.5 to 2.0

October 2025 Article in

*The Annals of Thoracic Surgery*²

Independent study of over 100K patients showed:

- ✓ Higher 10-year freedom from mortality or reoperation in patients ≤65 years with mechanical AVR (87%) vs with bioprosthetic AVR (69%)

January 2025 Article in

*JACC: Journal of The American College of Cardiology*³

Independent study of over 100K patients showed:

- ✓ Statistically significant mortality benefit of mechanical vs bioprosthetic AVR at 10yrs in patients ≤60 years



1. Gerdtsch MW, et al. Low-Dose Warfarin with a Novel Mechanical Aortic Valve: Interim Registry Results at 5-Year Follow-Up. *J Thorac Cardiovasc Surg* (2024). doi: <https://doi.org/10.1016/j.jtcvs.2024.04.017>. 2. Artivion data on file, weighted average of control groups from FDA Premarket Approval P000037 S030 and IDE trial G050208.


2. Kaneko T, et al. Reoperation in Bioprosthetic vs Mechanical Aortic Valve Replacement in The Society of Thoracic Surgeons Database. *The Annals of Thoracic Surgery* (2025) doi: <https://doi.org/10.1016/j.athoracsur.2025.09.047>.

3. Bowdish ME, Mehaffey JH, Chang S-C, O'Gara P, Mack MJ, Goldstone A, Chikwe J, Gillinov AM, Wu C, Fontana G, Bavaria J, Malaisrie C, Kaneko T, Sultan I, von Ballmoos MW, Harrington K, Jacobs J, Thourani V, Szeto W, Sabik J, Habib R, Badhwar V, Bioprosthetic vs. Mechanical Aortic Valve Replacement in Patients 40-75 Years. *Journal of American College of Cardiology* (2025) doi: <https://doi.org/10.1016/j.jacc.2025.01.013>.

ON-X LOW INR INDICATION DRIVING DURABLE DOUBLE-DIGIT GROWTH & SHARE GAINS*

ARTIVION™

Growth Accelerated by New Clinical Data Unlocking New Incremental \$100M U.S. Market



FY25
ON-X SALES
21%
GROWTH Y/Y

*Market share estimates derived from 2024 IQVIA Medical device supply audit and historical sales reports. Excludes MDT and CORCYM which combined are estimated to be <4% of total market share in 2024. FY25 On-X Sales Growth as of December 31, 2025 and future On-X market share expectations are not to scale

ARTIVION ABBOTT

HIGH GROWTH STENT GRAFT BUSINESS

- ✓ Focused on More Complex, Less Competitive Segments
- ✓ Artivion Stent Graft Growth: 18% 3-year CAGR

Advanced Stent Graft Segment

MARKET GROWTH RATE: MID-TEENS

Frozen Elephant Trunk (E-vita™ Open Neo)
\$250M Global TAM

Acute Type A Dissection (AMDST™)
\$540M Global TAM

Endovascular Arch Branched System (NEXUS®)
\$600M Global TAM

Thoracoabdominal (E-nside™ / Extra Design)
\$480M Global TAM

Iliac (E-liac™)
\$140M Global TAM

**\$2B
TAM**

Mature Stent Graft Segment


MARKET GROWTH RATE: MID-SINGLE DIGITS

Thoracic (Artivex™)
\$700M Global TAM

Abdominal (E-tegra)
\$1.3B Global TAM

**Crowded
Competitive
Market**

**\$2B
TAM**




HUMANITARIAN DEVICE EXEMPTION ENABLES EARLY U.S. LAUNCH OF AMDS™

ARTIVION™

- ✓ High Growth, High Margin Business with Limited Competitive Alternatives
- ✓ Strong Early Market Traction with Unparalleled Clinical Benefits Supported by Growing Body of Evidence
- ✓ New MS-DRG Code 209, effective October 1, 2025
- ✓ PMA Approval Expected Mid-2026

\$150 Million Addressable Market Opportunity



1



PTFE felt cuff: strengthens the aortic tissue in preparation to perform the conventional polyester graft to aorta anastomosis.

2




Uncovered nitinol wire braided stent: stabilizes aortic wall and promotes remodeling

AMDS™ PERSEVERE US IDE Study Primary Endpoints **ARTIVION**

Full IDE data demonstrates AMDS use significantly lowers 30-day Major Adverse Events (MAEs) compared to hemiarach control

Through Hospital Discharge Data




ACUTE DEBAKEY TYPE I (ADTI) WITH MALPERFUSION

Hemiarach Reference Cohort Avg.¹ (n=790)

PERSEVERE²
(n=93)

| | >=1 MAE | |
|-------|----------------------------------|-------|
| 58.0% | | 26.9% |
| 34.6% | All-Cause Mortality | 9.7% |
| 20.9% | New Disabling Stroke | 10.8% |
| 24.1% | Renal Failure Requiring Dialysis | 19.4% |
| 10.5% | Myocardial Infarction | 0.0% |
| 45.0% | Distal Anastomotic New Entry | 0.0% |

Full 30-Day Data



Total patients with ≥ 1MAE
PERSEVERE: 27%
Goal: < 40%

30-day data demonstrate AMDS induced positive aortic remodeling in over 80% of patients³

1. Zindovic I, 2019, Pacini D, 2013, Girdauskas E, 2009, Geirsson A, 2007, and Bossone E, 2002.

2. Szeto WY, Fukuhara S, Fleischman F, Sultan I, Brinkman W, Arnaoutakis G, Takayama H, Eudailey K, Brinster D, Jassar A, DeRose J, Brown C, Farrington W, Moon MC. A novel hybrid prosthesis for open repair of acute DeBakey type I dissection with malperfusion: Early results from the PERSEVERE trial. J Thorac Cardiovasc Surg. 2024 Aug 6:S0022-5223(24)00677-9.

3. Adjudicated data as presented at AATS April 2024, manuscript pending publication

R&D PIPELINE

ARTIVION™

| | | Regulatory Path | Addressable Market | 2026 | 2027 | 2028 | 2029 | |
|------------------------------------------------------------------------------------------------------------------------------------------------|---------|-----------------|--------------------|------|------|------|------|--------|
| Hybrid Acute Type A Dissection (ATAD) Prosthesis AMDS  | US PMA* | \$150M | ■ | | | | | |
| | Japan | \$75M | ■ | | | | | |
| Endovascular Arch Branch System Endospan's NEXUS  | US PMA | \$150M | ■ | | | | | |
| | Japan | \$100M | ■ | | | | | |
| Hybrid Frozen Elephant Trunk Arcevo LSA  | US PMA | \$80M | ■ | | | | | |
| | Japan | \$50M | ■ | | | | | > 2029 |
| Endovascular Thoracoabdominal System  | US PMA | \$325M | ■ | | | | | > 2029 |
| | EU | \$50M | ■ | | | | | > 2029 |

TOTAL OPPORTUNITY ~\$1 B

*AMDS is commercially available in the U.S. following receipt of Humanitarian Device Exemption

EndospaN NEXUS[®] TRIOMPHE US IDE Trial

30-day data demonstrate 63% reduction in major adverse event (MAE) rate compared to the reference performance goal

Presented at
AATS 2025



| 30-DAY DATA ¹ | TRIOMPHE (n=54) | Performance Goal | p Value |
|--------------------------|-----------------|------------------|---------|
| MAEs ² >=1 | 13.0% | 35.0% | p<0.001 |
| Technical Failure | 1.9% | 30.0% | p<0.001 |

30-DAY KEY TAKEAWAYS

- FDA investigational device exemption (IDE) trial for endovascular treatment of chronic dissections in the aortic arch; focused on patients at high risk for open surgery
- 30-day data demonstrates statistically significant improvement in clinical outcomes and device technical performance compared with performance goals set forth in the FDA-approved IDE
- Stroke and renal failure rates particularly favorable compared to published data for alternative endovascular treatments

1-year data demonstrate high patient survival with low morbidity [STS 2026]

- 94% patient survival from lesion-related death
- 91% free from disabling stroke
- 97% of patients free from reinterventions due to endoleaks

PROJECT STATUS (FORECAST COMPLETIONS)

| | |
|------------|------|
| Enrollment | 4Q24 |
| Follow Up | 4Q25 |
| Approval | 2H26 |

Source: EndospaN Ld

1. References for PG: Bashir et al. *Aorta* 2014; Brat et al. *JCTS*, 2015; Chakos et al. *Ann Cardiothorac Surg* 2018; DeRango et al. *J Vasc Surg* 2015; Hiraoka et al. *JTCVS*, 2017; Iba et al. *JTCVS* 2013; Joo et al. *JTCVS* 2018; Thomas et al. *JTCVS*, 2012

2. MAE includes: Early Mortality, Disabling Stroke, Permanent Paralysis/Paraplegia, Renal Failure (Permanent Dialysis), Aortic Rupture

ARTIZEN PIVOTAL IDE STUDY

ARTIVION™

Prospective, Non-randomized, Non-blinded, Double-arm, Multicenter (US & EU ≈ 30 Sites)

PRIMARY PATIENT GROUP

117 patients: Chronic dissection or Aneurysm

Primary endpoint: Freedom from major adverse events (MAEs) within 1-year post-index procedure: all-cause mortality, new permanent disabling stroke, new permanent paraplegia and/or paraparesis, unanticipated aortic reoperation in the treated segment, LSA occlusion

SECONDARY PATIENT GROUP

15 patients: Acute or subacute dissection

Descriptive statistics: No pre-defined endpoint

REFERENCE COHORT

Historical controls freedom from MAE rate of 59%.

Positive outcome is freedom from MAE composite $\geq 74\%$

STUDY STATUS

| | |
|----------------------------|-------------|
| 1 ST Enrollment | Nov 2025 |
| Enrollment | ~ 2025-2027 |
| Follow Up | ~ 2027-2028 |
| Approval | ~ 2029 |



DIFFERENTIATED BUSINESS MODEL WITH HIGHLY LEVERAGEABLE GLOBAL INFRASTRUCTURE

Significant EBITDA Margin Expansion Opportunity



Gross Margin Expansion

Highly Accretive Product Pipeline

Increased U.S. Mix Benefit from AMDS HDE Approval and On-X Market Expansion

Expected Double Digit Revenue Growth



Scalable Global Sales Force

~200 Global Direct Sales Employees

Focused on Cardiac/Vascular Surgeons Treating Aortic Disease

Minimal Case Support Required

Demonstrated Leverage:
12% 3-year CC Revenue CAGR vs 5% Direct Sales Employee Headcount CAGR



Reinvesting in R&D

Consistent investment of 7-8% of sales

Strong Balance Sheet Enables Self-Funding of Best-in-Class Pipeline to Unlock Incremental Market Opportunities



Leverageable Global G&A Infrastructure

Public Company Since 1993


No Major Location Additions Since 2017

~1,800 Employees Worldwide


EBITDA MARGIN EXPANSION & DELEVERAGING

Supported by Strong Balance Sheet & Prudent Capital Management

ADJUSTED EBITDA MARGIN




NET DEBT LEVERAGE



FULL YEAR 2026 REVENUE GUIDANCE

GROWTH DRIVERS

- + **Continued strength in existing products**
On-X and aortic stents
- + **Positive new data** supporting the benefits of AMDS and On-X aortic valves
- + **Continued adoption of AMDS** following receipt of Humanitarian Device Exemption by the FDA




REVENUE GROWTH AND OPERATING LEVERAGE TO DRIVE ADJUSTED EBITDA EXPANSION

FULL YEAR 2026 ADJUSTED EBITDA EXPECTATIONS

DRIVERS

Expect continued operating leverage to be driven by gross margin expansion, global sales force and G&A infrastructure





ARTIVION™

Thank you